Breaking News

Takeda to Acquire Oral Allosteric TYK2 Inhibitor from Nimbus Therapeutics

Acquisition expands Takeda’s late-stage pipeline and therapeutic expertise in immune-mediated diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda will acquire NDI-034858 from Nimbus Therapeutics, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases, including psoriasis. When the transaction is complete, NDI-034858 will be known as TAK-279.   Takeda will pay $4 billion upfront, and two milestone payments of $1 billion each upon achieving annual sales of $4 billion and $5 billion. The transaction is expected to be finalized before the end of FY2022.    ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters